Inflammation and cancer: advances and new agents

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · see citing works

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,314 · see citing works

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · see citing works

Cancer-related inflammation

Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399 · see citing works

Macrophage activation and polarization: nomenclature and experimental guidelines

Murray, P. J., Allen, J. E., Biswas, S. K., Fisher, E. A., Gilroy, D. W., Goerdt, S., Gordon, S., Hamilton, J. A., Ivashkiv, L. B., Lawrence, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.008 · Cited by 6,337 · see citing works

Involvement of chemokine receptors in breast cancer metastasis

Müller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S. N., et al. (2001) · Nature · doi:10.1038/35065016 · Cited by 5,340 · see citing works

The immune contexture in human tumours: impact on clinical outcome

Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981 · see citing works

Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment

Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632 · see citing works

An endotoxin-induced serum factor that causes necrosis of tumors

Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N., & Williamson, B. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.9.3666 · Cited by 4,532 · see citing works

Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer

Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M. J., Obenauf, A. C., Angell, H. K., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,390 · see citing works

Nivolumab plus Ipilimumab in Advanced Melanoma

Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · see citing works

Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion

Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759 · see citing works

Coordinated regulation of myeloid cells by tumours

Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · see citing works

Nuclear factor-κB in cancer development and progression

Karin, M. (2006) · Nature · doi:10.1038/nature04870 · Cited by 3,519 · see citing works

Tumour-educated macrophages promote tumour progression and metastasis

Pollard, J. W. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1256 · Cited by 3,365 · see citing works

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Brahmer, J. R., Drake, C. G., WOLLNER, I. S., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,967 · see citing works

Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis

Condeelis, J. S., & Pollard, J. W. (2006) · Cell · doi:10.1016/j.cell.2006.01.007 · Cited by 2,693 · see citing works

Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas

Eberhart, C. E., Coffey, R. J., Aramandla, R., Giardiello, F. M., Ferrenbach, S., & DuBois, R. N. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90246-1 · Cited by 2,512 · see citing works

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

Powles, T. B., Eder, J. P., Fine, G. D., Braiteh, F. S., Loriot, Y., Cruz, C., Joaquim Bellmunt, B., Burris, H. A., Petrylak, D. P., Teng, S.-L. M., et al. (2014) · Nature · doi:10.1038/nature13904 · Cited by 2,383 · see citing works

Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment

Iida, N., Dzutsev, A., Stewart, C. A., Smith, L., Bouladoux, N., Weingarten, R. A., Molina, D. A., Salcedo, R., Back, T., Cramer, S., et al. (2013) · Science · doi:10.1126/science.1240527 · Cited by 2,251 · see citing works

Interleukin-8 as a macrophage-derived mediator of angiogenesis

Koch, A. E., Polverini, P. J., Kunkel, S. L., Harlow, L. A., DiPietro, L. A., Elner, V. M., Elner, S. G., & Strieter, R. M. (1992) · Science · doi:10.1126/science.1281554 · Cited by 2,135 · see citing works

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110557 · Cited by 2,103 · see citing works

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer

Feig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320318110 · Cited by 2,100 · see citing works

Help for cytotoxic-T-cell responses is mediated by CD40 signalling

Bennett, S. R. M., Carbone, F., Karamalis, F., Flavell, R. A., Miller, J. F. A. P., & Heath, W. R. (1998) · Nature · doi:10.1038/30996 · Cited by 2,091 · see citing works

Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6

Yonish-Rouach, E., Resnftzky, D., Lotem, J., Sachs, L., Kimchi, A., & Oren, M. (1991) · Nature · doi:10.1038/352345a0 · Cited by 2,079 · see citing works

The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide

Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C., Pittet, M. J., et al. (2013) · Science · doi:10.1126/science.1240537 · Cited by 2,050 · see citing works

The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapies

Bingle, L., Brown, N. J., & Lewis, C. E. (2002) · The Journal of Pathology · doi:10.1002/path.1027 · Cited by 2,022 · see citing works

Gender Disparity in Liver Cancer Due to Sex Differences in MyD88-Dependent IL-6 Production

Naugler, W. E., Sakurai, T., Kim, S., Maeda, S., Kim, K., Elsharkawy, A. M., & Karin, M. (2007) · Science · doi:10.1126/science.1140485 · Cited by 1,955 · see citing works

Tumour necrosis factor and cancer

Balkwill, F. R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2628 · Cited by 1,925 · see citing works

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899 · see citing works

Properties Of The Novel Proinflammatory Supergene Intercrine Cytokine Family

Oppenheim, J. J., Zachariae, C. O. C., Mukaida, N., & Matsushima, K. (1991) · Annual Review of Immunology · doi:10.1146/annurev.iy.09.040191.003153 · Cited by 1,878 · see citing works

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

Harrison, C., Kiladjian, J.-J., Al-Ali, H. K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D. S., Levy, R., Knoops, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110556 · Cited by 1,825 · see citing works

CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W., Huhn, R. D., Song, W., Li, D., Sharp, L. L., et al. (2011) · Science · doi:10.1126/science.1198443 · Cited by 1,678 · see citing works

Contribution of platelets to tumour metastasis

Gay, L. J., & Felding‐Habermann, B. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3004 · Cited by 1,646 · see citing works

NF‐κB and the link between inflammation and cancer

DiDonato, J. A., Mercurio, F., & Karin, M. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01099.x · Cited by 1,490 · see citing works

Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated

Demaria, S., Ng, B., Devitt, M. L., Babb, J. S., Kawashima, N., Liebes, L., & Formenti, S. C. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.09.012 · Cited by 1,393 · see citing works

Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.

Ries, C. H., Cannarile, M. A., Hoves, S., Benz, J., Wartha, K., Runza, V., Rey-Giraud, F., Pradel, L. P., Feuerhake, F., Klaman, I., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.016 · Cited by 1,384 · see citing works

CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models

Zhu, Y., Knolhoff, B. L., Meyer, M. A., Nywening, T. M., West, B. L., Luo, J., Wang-Gillam, A., Goedegebuure, S. P., Linehan, D. C., & DeNardo, D. G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3723 · Cited by 1,324 · see citing works

Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors.

Masferrer, J. L., Leahy, K. M., Koki, A. T., Zweifel, B. S., Settle, S. L., Woerner, B. M., Edwards, D. A., Flickinger, A. G., Moore, R. J., & Seibert, K. (2000) · PubMed · Cited by 1,292 · see citing works

Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?

Coussens, L. M., Zitvogel, L., & Palucka, A. K. (2013) · Science · doi:10.1126/science.1232227 · Cited by 1,070 · see citing works

The Neutrophil-Activating Protein (NAP-1) Is Also Chemotactic for T Lymphocytes

Grønhøj, C., Anderson, A. O., Appella, E., Oppenheim, J. J., & Matsushima, K. (1989) · Science · doi:10.1126/science.2648569 · Cited by 1,037 · see citing works

Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone.

Taichman, R. S., Cooper, C. R., Keller, E. T., Pienta, K. J., Taichman, N. S., & McCauley, L. K. (2002) · PubMed · Cited by 994 · see citing works

Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials

Rothwell, P. M., Wilson, M., Price, J. F., Belch, J. F., Meade, T. W., & Mehta, Z. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60209-8 · Cited by 984 · see citing works

Targeting Tumor-Infiltrating Macrophages Decreases Tumor-Initiating Cells, Relieves Immunosuppression, and Improves Chemotherapeutic Responses

Mitchem, J. B., Brennan, D. J., Knolhoff, B. L., Belt, B. A., Zhu, Y., Sanford, D. E., Belaygorod, L., Carpenter, D. H., Collins, L. I., Piwnica-Worms, D. R., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2731 · Cited by 943 · see citing works

Role of Macrophage Targeting in the Antitumor Activity of Trabectedin

Germano, G., Frapolli, R., Belgiovine, C., Anselmo, A., Pesce, S., Liguori, M., Erba, E., Uboldi, S., Zucchetti, M., Pasqualini, F., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.01.008 · Cited by 863 · see citing works

Stat proteins and oncogenesis

Bromberg, J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15617 · Cited by 846 · see citing works

TNF-α in promotion and progression of cancer

Balkwill, F. (2006) · Cancer Metastasis Review · doi:10.1007/s10555-006-9005-3 · Cited by 844 · see citing works

Aspirin Use, Tumor PIK3CA Mutation, and Colorectal-Cancer Survival

Liao, X., Lochhead, P. J., Nishihara, R., Morikawa, T., Kuchiba, A., Yamauchi, M., Imamura, Y., Qian, Z. R., Baba, Y., Shima, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207756 · Cited by 842 · see citing works

Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials

Rothwell, P. M., Price, J. F., Fowkes, F. G. R., Zanchetti, A., Roncaglioni, M. C., Tognoni, G., Lee, R., Belch, J. F., Wilson, M., Mehta, Z., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61720-0 · Cited by 839 · see citing works

Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials

Algra, A. M., & Rothwell, P. M. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70112-2 · Cited by 833 · see citing works

Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists.

Mohler, K. M., Torrance, D., Smith, C., Goodwin, R., Stremler, K. E., Fung, V., Madani, H., & Widmer, M. B. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.3.1548 · Cited by 832 · see citing works

Paraneoplastic thrombocytosis in ovarian cancer

Stone, R. L., Nick, A. M., McNeish, I. A., Balkwill, F., Han, H. D., Bottsford-Miller, J., Rupaimoole, R., Armaiz-Pena, G. N., Pecot, C. V., Coward, J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110352 · Cited by 812 · see citing works

Inflammation: Gearing the journey to cancer

Kundu, J. K., & Surh, Y. (2008) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2008.03.002 · Cited by 804 · see citing works

CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts

Ginestier, C., Liu, S., Diebel, M. E., Körkaya, H., Luo, M., Brown, M., Wicinski, J., Cabaud, O., Charafe‐Jauffret, E., Birnbaum, D., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci39397 · Cited by 761 · see citing works

Expression of cyclooxygenase-2 in human lung carcinoma.

Wolff, H. J., Saukkonen, K., Anttila, S. L., Karjalainen, A., Vainio, H., & Ristimaki, A. P. (1998) · PubMed · Cited by 722 · see citing works

Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck.

Chan, G. G., Boyle, J. O., Yang, E. K., et al. (1999) · PubMed · Cited by 717 · see citing works

CXCR4 Regulates Growth of Both Primary and Metastatic Breast Cancer

Smith, M. C. P., Luker, K. E., Garbow, J. R., Prior, J. L., Jackson, E. N., Piwnica-Worms, D. R., & Luker, G. D. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1844 · Cited by 715 · see citing works

IL-6 and related cytokines as the critical lynchpins between inflammation and cancer

Taniguchi, K., & Karin, M. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.01.001 · Cited by 713 · see citing works

Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer.

Hwang, D., Scollard, D., Byrne, J., & Levine, E. (1998) · Journal of the National Cancer Institute · doi:10.1093/jnci/90.6.455 · Cited by 705 · see citing works

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

Knight, D. M., Trinh, H., Le, J., Siegel, S. A., Shealy, D. J., McDonough, M., Scallon, B. J., Moore, M. A., Vilček, J., Daddona, P. E., et al. (1993) · Molecular Immunology · doi:10.1016/0161-5890(93)90106-l · Cited by 704 · see citing works

Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer.

Tucker, O., Dannenberg, A. J., Yang, E. K., Zhang, F., Teng, L., Daly, J. M., Soslow, R. A., Masferrer, J. L., Woerner, B. M., Koki, A. T., et al. (1999) · PubMed · Cited by 690 · see citing works

Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas

Gao, S. P., Mark, K. G., Leslie, K., Pao, W., Motoi, N., Gerald, W. L., Travis, W. D., Bornmann, W., Veach, D., Clarkson, B., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31871 · Cited by 666 · see citing works

COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer

Buckman, S. (1998) · Carcinogenesis · doi:10.1093/carcin/19.5.723 · Cited by 593 · see citing works

CSF1R Signaling Blockade Stanches Tumor-Infiltrating Myeloid Cells and Improves the Efficacy of Radiotherapy in Prostate Cancer

Xu, J., Escamilla, J., Mok, S., David, J., Priceman, S. J., West, B. L., Bollag, G. E., McBride, W. H., & Wu, L. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3981 · Cited by 571 · see citing works

Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational study

Wolfe, F., & Michaud, K. D. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22864 · Cited by 537 · see citing works

Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules

Demetri, G. D., Chawla, S. P., von Mehren, M., Ritch, P. S., Baker, L. H., Blay, J., Hande, K. R., Keohan, M. L., Samuels, B. L., Schuetze, S. M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.0088 · Cited by 537 · see citing works

Sulindac for polyposis of the colon

Waddell, W. R., & Loughry, R. W. (1983) · Journal of Surgical Oncology · doi:10.1002/jso.2930240119 · Cited by 516 · see citing works

KrasG12D-Induced IKK2/β/NF-κB Activation by IL-1α and p62 Feedforward Loops Is Required for Development of Pancreatic Ductal Adenocarcinoma

Ling, J., Kang, Y., Zhao, R., Xia, Q., Lee, D.-F., Chang, Z., Li, J., Peng, B., Fleming, J. B., Wang, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.12.006 · Cited by 513 · see citing works

CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy

Diehl, L., den Boer, A. T., Schoenberger, S. P., van der Voort, E. I. H., Schumacher, T. N., Melief, C. J. M., Offringa, R., & Toes, R. E. M. (1999) · Nature Medicine · doi:10.1038/10495 · Cited by 468 · see citing works

Inflammation and oncogenesis: a vicious connection

Grivennikov, S. I., & Karin, M. (2009) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2009.11.004 · Cited by 460 · see citing works

A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma

Beatty, G. L., Torigian, D. A., Chiorean, E. G., Saboury, B., Brothers, A., Alavi, A. A., Troxel, A. B., Sun, W., Teitelbaum, U. R., Vonderheide, R. H., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1320 · Cited by 458 · see citing works

Antitumor Necrosis Factor Therapy for Inflammatory Bowel Disease: A Review of Agents, Pharmacology, Clinical Results, and Safety

Sandborn, W. J., & Hanauer, S. B. (1999) · Inflammatory Bowel Diseases · doi:10.1097/00054725-199905000-00008 · Cited by 456 · see citing works

Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis

Jung, Y., Kim, J. K., Shiozawa, Y., Wang, J., Mishra, A., Joseph, J., Berry, J. E., McGee, S., Lee, E., Sun, H., et al. (2013) · Nature Communications · doi:10.1038/ncomms2766 · Cited by 424 · see citing works

Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis

Ancrile, B., Lim, K.-H., & Counter, C. M. (2007) · Genes & Development · doi:10.1101/gad.1549407 · Cited by 422 · see citing works

Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists

Askling, J., Fored, C. M., Baecklund, E., et al. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.033241 · Cited by 419 · see citing works

Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer

Pienta, K. J., Machiels, J.-P., Schrijvers, D. L. A. L., Alekseev, B. Y., Shkolnik, M. I., Crabb, S. J., Li, S., Seetharam, S., Puchalski, T. A., Takimoto, C. H. M., et al. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9869-8 · Cited by 413 · see citing works

IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor.

Schadendorf, D., Möller, A., Algermissen, B., Worm, M., Sticherling, M., & Czarnetzki, B. M. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.5.2667 · Cited by 412 · see citing works

Sulindac for polyposis of the colon

Waddell, W. R., Ganser, G. F., Cerise, E. J., & Loughry, R. W. (1989) · The American Journal of Surgery · doi:10.1016/0002-9610(89)90442-x · Cited by 409 · see citing works

A Possible Role for CXCR4 and Its Ligand, the CXC Chemokine Stromal Cell-Derived Factor-1, in the Development of Bone Marrow Metastases in Neuroblastoma

Geminder, H., Sagi‐Assif, O., Goldberg, L., Meshel, T., Rechavi, G., Witz, I. P., & Ben‐Baruch, A. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.8.4747 · Cited by 408 · see citing works

Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40

Sotomayor, E. M., Borrello, I., Tubb, E. E., Rattis, F., Bien, H., Lu, Z., Fein, S., Schoenberger, S. P., & Levitsky, H. I. (1999) · Nature Medicine · doi:10.1038/10503 · Cited by 406 · see citing works

Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis

Xavier Mariette, A., Matucci‐Cerinic, M., Pavelká, K., Taylor, P. C., van Vollenhoven, R., Heatley, R., Walsh, C., Lawson, R., Reynolds, A., & Emery, P. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.149419 · Cited by 403 · see citing works

The Inflammatory Cytokine Tumor Necrosis Factor-α Generates an Autocrine Tumor-Promoting Network in Epithelial Ovarian Cancer Cells

Kulbe, H., Thompson, R. D., Wilson, J. L., Robinson, S., Hagemann, T., Fatah, R., Gould, D., Ayhan, A., & Balkwill, F. R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2941 · Cited by 396 · see citing works

Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer

Coward, J. I. G., Kulbe, H., Chakravarty, P., Leader, D., Vassileva, V., Leinster, D. A., Thompson, R. D., Schioppa, T., Nemeth, J., VERMEULEN, J. T., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0945 · Cited by 388 · see citing works

Interleukin-8. A corneal factor that induces neovascularization.

Strieter, R. M., Kunkel, S. L., Elner, V. M., Mártonyi, C. L., Koch, A. E., Polverini, P. J., & Elner, V. M. (1992) · PubMed Central · Cited by 383 · see citing works

Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists

Askling, J., Fored, C. M., Brandt, L., et al. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.033993 · Cited by 380 · see citing works

Tumour necrosis factor-α as a tumour promoter

Szlosarek, P. W., Charles, K. A., & Balkwill, F. R. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.012 · Cited by 367 · see citing works

Estimates of benefits and harms of prophylactic use of aspirin in the general population

Cuzick, J., Thorat, M., Bosetti, C., Brown, P., Burn, J., Cook, N., Ford, L., Jacobs, E., Jankowski, J., la Vecchia, C., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu225 · Cited by 363 · see citing works

Fully Humanized Neutralizing Antibodies to Interleukin-8 (ABX-IL8) Inhibit Angiogenesis, Tumor Growth, and Metastasis of Human Melanoma

Huang, S., Mills, L., Mian, B. M., Tellez, C. S., McCarty, M. F., Yang, X., Gudas, J. M., & Bar‐Eli, M. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64164-8 · Cited by 361 · see citing works

The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events

Leombruno, J. P., Einarson, T. R., & Keystone, E. C. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.091025 · Cited by 361 · see citing works

Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy

Priceman, S. J., Sung, J. L., Shaposhnik, Z., Burton, J. B., Torres‐Collado, A. X., Moughon, D. L., Johnson, M., Lusis, A. J., Cohen, D. A., Iruela‐Arispe, M. L., et al. (2009) · Blood · doi:10.1182/blood-2009-08-237412 · Cited by 357 · see citing works

Identification of Human S100A9 as a Novel Target for Treatment of Autoimmune Disease via Binding to Quinoline-3-Carboxamides

Björk, P., Björk, A., Vogl, T., Stenström, M., Liberg, D., OLSSON, A. G., Roth, J., Ivars, F., & Leanderson, T. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000097 · Cited by 357 · see citing works

The effect of methotrexate and anti–tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 PERSON‐YEARS of observation

Wolfe, F., & Michaud, K. D. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22579 · Cited by 350 · see citing works

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study

Goy, A. H., Bernstein, S. H., Kahl, B. S., Djulbegović, B., Robertson, M. J., de Vos, S., Epner, E. M., Krishnan, A., Leonard, J. P., Lonial, S., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn656 · Cited by 335 · see citing works

Cytokines as a key component of cancer-related inflammation

Germano, G., Allavena, P., & Mantovani, A. (2008) · Cytokine · doi:10.1016/j.cyto.2008.07.014 · Cited by 331 · see citing works

Inhibition of CSF-1 Receptor Improves the Antitumor Efficacy of Adoptive Cell Transfer Immunotherapy

Mok, S., Koya, R. C., Tsui, C. T., Xu, J., Robert, L., Wu, L., Graeber, T. G., West, B. L., Bollag, G. E., & Ribas, A. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1816 · Cited by 311 · see citing works

Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta‐analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data

Askling, J., Fahrbach, K. R., Nordstrom, B. L., et al. (2010) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2046 · Cited by 306 · see citing works

Tumor-Recruited Neutrophils and Neutrophil TIMP-Free MMP-9 Regulate Coordinately the Levels of Tumor Angiogenesis and Efficiency of Malignant Cell Intravasation

Bekes, E. M., Schweighofer, B., Kupriyanova, T. A., Zając, E., Ardi, V. C., Quigley, J. P., & Deryugina, E. I. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.05.031 · Cited by 299 · see citing works

Stromal Cell-Derived Factor 1, a Novel Target of Estrogen Receptor Action, Mediates the Mitogenic Effects of Estradiol in Ovarian and Breast Cancer Cells

Hall, J. M., & Korach, K. S. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0438 · Cited by 295 · see citing works

Anti-inflammatory Properties of the Novel Antitumor Agent Yondelis (Trabectedin): Inhibition of Macrophage Differentiation and Cytokine Production

Allavena, P., Signorelli, M., Chieppa, M., Erba, E., Bianchi, G., Marchesi, F., Olimpio, C. O., Bonardi, C., Garbi, A., Lissoni, A. A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4037 · Cited by 286 · see citing works

Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder.

Mohammed, S. I., Knapp, D. W., Bostwick, D. G., Foster, R. S., Khan, K. N. M., Masferrer, J. L., Woerner, B. M., Snyder, P. W., & Koki, A. T. (1999) · PubMed · Cited by 285 · see citing works

Statin use and cancer risk: a comprehensive review

Boudreau, D. M., Yu, O., & Johnson, J. (2010) · Expert Opinion on Drug Safety · doi:10.1517/14740331003662620 · Cited by 274 · see citing works

A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors

Sandhu, S. K., Papadopoulos, K. P., Fong, P. C. C., Patnaik, A., Messiou, C., Olmos, D., Wang, G., Tromp, B. J., Puchalski, T. A., Balkwill, F. R., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2099-8 · Cited by 273 · see citing works

Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma

Miguel, J. F. S., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M. H., Špıčka, I., Petrucci, M. T., Palumbo, A. P., Samoilova, O. S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6180 · Cited by 263 · see citing works

IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer

Anglesio, M. S., George, J., Kulbe, H., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3314 · Cited by 262 · see citing works

Stromal Cell–Derived Factor-1α and CXCR4 Expression in Hemangioblastoma and Clear Cell-Renal Cell Carcinoma: von Hippel-Lindau Loss-of-Function Induces Expression of a Ligand and Its Receptor

Zagzag, D., Krishnamachary, B., Yee, H. T., Okuyama, H., Chiriboga, L. A., Ali, M., Melamed, J., & Semenza, G. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4406 · Cited by 260 · see citing works

Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins

Sanmamed, M. F., Carranza-Rua, O., Alfaro, C., Oñate, C., Martín‐Algarra, S., Pérez, G., Landazuri, S. F., González, Á., Groß, S., Rodríguez, I., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3203 · Cited by 256 · see citing works

Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases

Kim, S. Y., Lee, C. H., Midura, B., Yeung, C. L., Mendoza, A., Hong, S. H., Ren, L., Wong, D., Korz, W., Merzouk, A., et al. (2007) · Clinical & Experimental Metastasis · doi:10.1007/s10585-007-9133-3 · Cited by 253 · see citing works

Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression.

Naylor, M. S., Stamp, G., Foulkes, W. D., Eccles, D., & Balkwill, F. R. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116446 · Cited by 252 · see citing works

Tumor Necrosis Factor α As a New Target for Renal Cell Carcinoma: Two Sequential Phase II Trials of Infliximab at Standard and High Dose

Harrison, M., Obermueller, E., Maisey, N. R., Hoare, S., Edmonds, K., Li, N. F., Chao, D., Hall, K., Lee, C., Timotheadou, E. T., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.2136 · Cited by 251 · see citing works

Interleukin-8/CXCL8 is a growth factor for human lung cancer cells

Zhu, Y., Webster, S. J., Flower, D., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602227 · Cited by 243 · see citing works

Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-α and TGF-β

Stuelten, C. H., Byfield, S. D., Arany, P. R., Karpova, T., Stetler‐Stevenson, W. G., & Roberts, A. B. (2005) · Journal of Cell Science · doi:10.1242/jcs.02334 · Cited by 236 · see citing works

Anti-Angiogenic and Anti-Inflammatory Effects of Statins: Relevance to Anti-Cancer Therapy

Dulak, J., & Józkowicz, A. (2005) · Current Cancer Drug Targets · doi:10.2174/156800905774932824 · Cited by 235 · see citing works

Involvement of SDF‐1α/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma

Kajiyama, H., Shibata, K., Terauchi, M., Ino, K., Nawa, A., & Kikkawa, F. (2007) · International Journal of Cancer · doi:10.1002/ijc.23083 · Cited by 220 · see citing works

Clinical and Correlative Results of SWOG S0354: a Phase II Trial of CNTO328 (siltuximab), a Monoclonal Antibody against Interleukin-6 (IL-6), in Chemotherapy Pre-treated Patients with Castration-Resistant Prostate Cancer (CRPC)

Dorff, T., Goldman, B., Pinski, J., Mack, P., Lara, P., Veldhuizen, P. V., Quinn, D., Vogelzang, N., Thompson, I., & Hussain, M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3122 · Cited by 219 · see citing works

The role of cytokines in cancer cachexia

Argilés, J. M. A., Busquets, S., Toledo, M., & López-Soriano, F. J. (2009) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0b013e3283311d09 · Cited by 211 · see citing works

Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer

Пили, Р., Häggman, M., Stadler, W. M., Gingrich, J. R., Assikis, V. J., Björk, A., Nordle, Ö., Forsberg, G., Carducci, M. A., & Armstrong, A. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6295 · Cited by 208 · see citing works

A Phase II Study of Etanercept (Enbrel), a Tumor Necrosis Factor α Inhibitor in Patients with Metastatic Breast Cancer

Madhusudan, S., Foster, M., Muthuramalingam, S. R., Braybrooke, J. P., Wilner, S., Kaur, K., Han, C., Hoare, S., Balkwill, F. R., Talbot, D. C., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0730 · Cited by 205 · see citing works

A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease

Kurzrock, R., Voorhees, P., Casper, C., Furman, R., Fayad, L., Lonial, S., Borghaei, H., Jagannath, S., Sokol, L., Usmani, S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3349 · Cited by 202 · see citing works

β1 Integrin Adhesion Enhances IL-6–Mediated STAT3 Signaling in Myeloma Cells: Implications for Microenvironment Influence on Tumor Survival and Proliferation

Shain, K. H., Yarde, D. N., Meads, M. B., Huang, M., Jove, R., Hazlehurst, L., & Dalton, W. S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2419 · Cited by 200 · see citing works

MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study

Hong, D. S., Hui, D., Bruera, E. D., Jankú, F., Naing, A., Falchook, G. S., Piha-Paul, S. A., Wheler, J. J., Fu, S., Tsimberidou, A. M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70155-x · Cited by 198 · see citing works

Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer

Fizazi, K. S., Bono, J. S. D., Fléchon, A., Heidenreich, A., Voog, É., Davis, N. B., Qi, M., Bandekar, R. R., VERMEULEN, J. T., Cornfeld, M. J., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.10.014 · Cited by 197 · see citing works

A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer

Rossi, J., Négrier, S., James, N. D., Kocák, I., Hawkins, R. E., Davis, H., Prabhakar, U., Qin, X., Mulders, P., & Berns, B. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605872 · Cited by 190 · see citing works

JAK1 Activates STAT3 Activity in Non-Small–Cell Lung Cancer Cells and IL-6 Neutralizing Antibodies Can Suppress JAK1-STAT3 Signaling

Song, L., Rawal, B., Nemeth, J. A., & Haura, E. B. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0502 · Cited by 178 · see citing works

Induction of haptotactic migration of melanoma cells by neutrophil activating protein/interleukin-8

Wang, J. M., Taraboletti, G., Matsushima, K., Damme, J. V., & Mantovani, A. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(90)91449-3 · Cited by 175 · see citing works

Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines.

Borsellino, N., Belldegrun, A. S., & Bonavida, B. (1995) · PubMed · Cited by 172 · see citing works

IL-1 alpha or tumor necrosis factor-alpha stimulate release of three NAP-1/IL-8-related neutrophil chemotactic proteins in human dermal fibroblasts.

Schröder, J. ‐., Sticherling, M., Henneicke, H. H., Preissner, W. C., & Christophers, E. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.144.6.2223 · Cited by 170 · see citing works

CXCR4 Signaling Regulates Metastasis of Chemoresistant Melanoma Cells by a Lymphatic Metastatic Niche

Kim, M., Koh, Y. J., Kim, K. E., Koh, B. I., Nam, D., Alitalo, K. K., Kim, I., & Koh, G. Y. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2591 · Cited by 170 · see citing works

Study of Etanercept, a Tumor Necrosis Factor-Alpha Inhibitor, in Recurrent Ovarian Cancer

Madhusudan, S., Muthuramalingam, S. R., Braybrooke, J. P., Wilner, S., Kaur, K., Han, C., Hoare, S., Balkwill, F. R., & Ganesan, T. S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.127 · Cited by 167 · see citing works

Radiation as an Immune Modulator

Burnette, B., & Weichselbaum, R. R. (2013) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2013.05.009 · Cited by 164 · see citing works

Targeting Toll-like Receptor 9 with CpG Oligodeoxynucleotides Enhances Tumor Response to Fractionated Radiotherapy

Mason, K. A., Ariga, H., Neal, R. E., Valdecanas, D. R., Hunter, N. R., Krieg, A. Μ., Whisnant, J. K., & Milas, L. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.361.11.1 · Cited by 153 · see citing works

CpG Oligodeoxynucleotide Enhances Tumor Response to Radiation

Milas, L., Mason, K. A., Ariga, H., Hunter, N. R., Neal, R. E., Valdecanas, D. R., Krieg, A. Μ., & Whisnant, J. K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0926 · Cited by 151 · see citing works

Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti–IL-6) in multiple myeloma

Miguel, J. F. S., Bladé, J., Shpilberg, O., Grosicki, S., Maloisel, F., Min, C., Zarzuela, M. P., Robak, T., Prasad, S. V. S. S., Goh, Y. T., et al. (2014) · Blood · doi:10.1182/blood-2013-12-546374 · Cited by 144 · see citing works

Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes

Younes, A., Romaguera, J. E., Fanale, M. A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.5223 · Cited by 142 · see citing works

CXC‐chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer

Matsuo, Y., Raimondo, M., Woodward, T. A., Wallace, M. B., Gill, K. R., Tong, Z., Burdick, M. D., Yang, Z., Strieter, R. M., Hoffman, R. M., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24383 · Cited by 138 · see citing works

Aspirin and COX-2 Inhibitor Use in Patients With Stage III Colon Cancer

Ng, K., Meyerhardt, J. A., Chan, A. T., Sato, K., Chan, J. A.-W., Niedzwiecki, D., Saltz, L. B., Mayer, R. J., Benson, A. B., Schaefer, P., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju345 · Cited by 137 · see citing works

Interleukin-6 gene expression in multiple myeloma: a characteristic of immature tumor cells

Hata, H., Xiao, H., Petrucci, M., et al. (1993) · Blood · doi:10.1182/blood.v81.12.3357.3357 · Cited by 136 · see citing works

A phase 2, randomized, double‐blind, placebo‐controlled study of siltuximab (anti‐IL‐6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma

Orlowski, R. Z., Gercheva, L., Williams, C. D., Sutherland, H. J., Robak, T., Masszi, T., Goranova-Marinova, V. S., Dimopoulos, M. A., Cavenagh, J. D., Špıčka, I., et al. (2014) · American Journal of Hematology · doi:10.1002/ajh.23868 · Cited by 133 · see citing works

IL-8 Reduced Tumorigenicity of Human Ovarian Cancer In Vivo Due to Neutrophil Infiltration

Lee, L., Hellendall, R. P., Wang, Y., Haskill, J. S., Mukaida, N., Matsushima, K., & Ting, J. P. ‐. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.5.2769 · Cited by 132 · see citing works

Cancer cachexia: the molecular mechanisms

Argilés, J. M. A., Moore‐Carrasco, R., Fuster, G., Busquets, S., & López-Soriano, F. J. (2003) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(02)00251-0 · Cited by 132 · see citing works

Serum concentration of tumor necrosis factor in patients with breast cancer

Sheen‐Chen, S., Chen, W., Eng, H., & Chou, F. (1997) · Breast Cancer Research and Treatment · doi:10.1023/a:1005736712307 · Cited by 132 · see citing works

Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia.

Ando, K., Takahashi, F., Motojima, S., Nakashima, K., Kaneko, N., Hoshi, K., & Takahashi, K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2020 · Cited by 131 · see citing works

Expression and regulation of tumor necrosis factor α in normal and malignant ovarian epithelium

Szlosarek, P. W., Grimshaw, M. J., Kulbe, H., Wilson, J. L., Wilbanks, G. D., Burke, F., & Balkwill, F. R. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0303 · Cited by 131 · see citing works

Chimaeric anti‐interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose‐escalating study

Zaanen, V., Lokhorst, Aarden, et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00835.x · Cited by 127 · see citing works

Symptoms tell it all: A systematic review of the value of symptom assessment to predict survival in advanced cancer patients

Trajkovic, M., de Graeff, A., Voest, E. E., & Teunissen, S. C. C. M. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.02.011 · Cited by 126 · see citing works

Expression of tumour necrosis factor (TNFα) and its receptors in benign and malignant breast tissue

Miles, D. W., Happerfield, L. C., Naylor, M. S., Bobrow, L. G., Rubens, R. D., & Balkwwill, F. R. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910560603 · Cited by 124 · see citing works

Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer

Strohmeyer, D., R�ssing, C., Strauss, F., Bauerfeind, A., Kaufmann, O., & Loening, S. A. (2000) · The Prostate · doi:10.1002/(sici)1097-0045(20000101)42:1 · Cited by 110 · see citing works

Anti-TNF Therapy, from Rationale to Standard of Care: What Lessons Has It Taught Us?

Feldmann, M., & Maini, R. N. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1090051 · Cited by 106 · see citing works

Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health–AARP Diet and Health Study

Gierach, G. L., Lacey, J. V., Schatzkin, A. G., Leitzmann, M. F., Richesson, D. A., Hollenbeck, A. R., & Brinton, L. A. (2008) · Breast Cancer Research · doi:10.1186/bcr2089 · Cited by 106 · see citing works

Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study

Fraser, D. M., Sullivan, F., Thompson, A. M., & McCowan, C. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.264 · Cited by 103 · see citing works

Use of Aspirin and Other Nonsteroidal Antiinflammatory Medications in Relation to Prostate Cancer Risk

Salinas, C. A., Kwon, E. M., FitzGerald, L. M., Feng, Z., Nelson, P. S., Ostrander, E. A., Peters, U., & Stanford, J. L. (2010) · American Journal of Epidemiology · doi:10.1093/aje/kwq175 · Cited by 94 · see citing works

Targeting Chemokine (C-C motif) Ligand 2 (CCL2) as an Example of Translation of Cancer Molecular Biology to the Clinic

Zhang, J., Patel, L. R., & Pienta, K. J. (2010) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-385071-3.00003-4 · Cited by 93 · see citing works

Taxol-dependent transcriptional activation of IL-8 expression in a subset of human ovarian cancer.

Lee, L. F., Schuerer-Maly, C. C., Lofquist, A. K., et al. (1996) · PubMed · Cited by 87 · see citing works

Cancer Risk of Anti-TNF-α at Recommended Doses in Adult Rheumatoid Arthritis: A Meta-Analysis with Intention to Treat and per Protocol Analyses

Moulis, G., Sommet, A., Béné, J., Montastruc, F., Sailler, L., Montastruc, J., & Lapeyre‐Mestre, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048991 · Cited by 82 · see citing works

Activation of human basophils through the IL-8 receptor

Krieger, M., Brunner, T., Bischoff, S. C., Tscharner, V., Walz, A., Moser, B., Baggiolini, M., & Dahinden, C. A. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.149.8.2662 · Cited by 81 · see citing works

A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer

Hudes, G., Tagawa, S., Whang, Y., Qi, M., Qin, X., Puchalski, T., Reddy, M., Cornfeld, M., & Eisenberger, M. (2013) · Investigational new drugs · doi:10.1007/s10637-012-9857-z · Cited by 71 · see citing works

Disrupting Cytokine Signaling in Pancreatic Cancer

Wu, C. S.-Y., Fernández, S., Criswell, T., Chidiac, T. A., D, D. C. G., Villalona-Calero, M. A., & Bekaii‐Saab, T. (2013) · Pancreas · doi:10.1097/mpa.0b013e318279b87f · Cited by 70 · see citing works

Interleukin 1 system and sex steroid receptor expression in human breast cancer: interleukin 1alpha protein secretion is correlated with malignant phenotype.

Singer, C. F., Kronsteiner, N., Hudelist, G., Márton, E., Walter, I., Kubista, M., Czerwenka, K. F., Schreiber, M., Seifert, M., & Kubista, E. (2003) · PubMed · Cited by 67 · see citing works

Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer

Ola Bratt, A., Häggman, M., Ahlgren, G., Nordle, Ö., Björk, A., & Damber, J. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605322 · Cited by 65 · see citing works

Inhibition of stromal CXCR4 impairs development of lung metastases

D’Alterio, C., Barbieri, A., Portella, L., Palma, G., Polimeno, M., Riccio, A., Ieranò, C., Franco, R., Scognamiglio, G., Bryce, J., et al. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1223-7 · Cited by 59 · see citing works

Blockade of CXCR4 in oral squamous cell carcinoma inhibits lymph node metastases

Uchida, D., Onoue, T., Kuribayashi, N., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.09.028 · Cited by 58 · see citing works

Radiation as Immunomodulator: Implications for Dendritic Cell-Based Immunotherapy

Roses, R. E., Datta, J., & Czerniecki, B. J. (2014) · Radiation Research · doi:10.1667/rr13495.1 · Cited by 49 · see citing works

Unique Features of the Mode of Action of ET-743

D’Incalci, M., Erba, E., Damia, G. L. M., Galliera, E., Carrassa, L., Marchini, S., Mantovani, R., Tognon, G., Fruscio, R., Jimeno, J. M., et al. (2002) · The Oncologist · doi:10.1634/theoncologist.7-3-210 · Cited by 46 · see citing works

Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer

Milagre, C. S., Gopinathan, G., Everitt, G. L. A., Thompson, R. G., Kulbe, H., Zhong, H., Hollingsworth, R. E., Grose, R. P., Bowtell, D. D. L., Hochhauser, D., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1801 · Cited by 42 · see citing works

A systematic review and meta-analysis of the efficacy and safety of adalimumab for treating rheumatoid arthritis

Wiens, A., Correr, C. J., Venson, R., et al. (2009) · Rheumatology International · doi:10.1007/s00296-009-1111-4 · Cited by 40 · see citing works

A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma

Larkin, J., Ferguson, T., Pickering, L. M., Edmonds, K., James, M. G., Thomas, K., Banerji, U., Berns, B., de Boer, C., & Gore, M. E. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605889 · Cited by 40 · see citing works

Intensive anti-inflammatory therapy with dexamethasone in patients with non-small cell lung cancer: effect on chemotherapy toxicity and efficacy

Leggas, M. L., Kuo, K., Robert, F., Cloud, G., deShazo, M., Zhang, R., Li, M., Wang, H., Davidson, S., & Rinehart, J. J. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0767-x · Cited by 31 · see citing works

Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer

Michaelson, M. D., Joaquim Bellmunt, B., Hudes, G. R., Goel, S., Lee, R. J., Kantoff, P. W., Stein, C., Lardelli, P., Pardos, I., Kahatt, C. M., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr399 · Cited by 30 · see citing works

Ovarian cancer-induced immunosuppression: relationship to tumor necrosis factor-alpha (TNF-alpha) release from ovarian tissue.

Hassan, M. I., Kassim, S. K., Saeda, L., Laban, M., & Khalifa, A. (1999) · PubMed · Cited by 22 · see citing works

Phase II, randomized, double blind, placebo-controlled study comparing siltuximab plus bortezomib versus bortezomib alone in pts with relapsed/refractory multiple myeloma.

Orlowski, R. Z., Gercheva, L., Williams, C. D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.8018 · Cited by 18 · see citing works

Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis

Bonapace, L., Coissieux, M., Wyckoff, J. B., Mertz, K. D., Varga, Z., Junt, T., & Bentires‐Alj, M. (2014) · Zurich Open Repository and Archive (University of Zurich) · doi:10.1038/nature13862 · Cited by 15 · see citing works

Untitled work

Berenson (2001) · doi:10.1002/1097-0142(20010401)91:7

Macrophages and metabolism in the tumor microenvironment

Vitale, I., Manic, G., Coussens, L. M., Kroemer, G., & Galluzzi, L. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.06.001 · Cited by 1,837 · see citing works

Improving cancer immunotherapy through nanotechnology

Goldberg, M. S. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0186-9 · Cited by 628 · see citing works

An inflammatory aging clock (iAge) based on deep learning tracks multimorbidity, immunosenescence, frailty and cardiovascular aging

Sayed, N., Huang, Y., Nguyen, K., Krejciova-Rajaniemi, Z., Grawe, A. P., Gao, T., Tibshirani, R., Hastie, T., Alpert, A., Cui, L., et al. (2021) · Nature Aging · doi:10.1038/s43587-021-00082-y · Cited by 572 · see citing works

GDF15 Is an Inflammation-Induced Central Mediator of Tissue Tolerance

Luan, H. H., Wang, A., Hilliard, B. K., Carvalho, F., Rosen, C. E., Ahasic, A. M., Herzog, E. L., Kang, I., Pisani, M. A., Yu, S., et al. (2019) · Cell · doi:10.1016/j.cell.2019.07.033 · Cited by 527 · see citing works

Chronic inflammation and the hallmarks of aging

Baechle, J. J., Chen, N., Makhijani, P., Winer, S., Furman, D., & Winer, D. A. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101755 · Cited by 471 · see citing works

Breast Cancer and Its Relationship with the Microbiota

Fernández, M. F., Reina-Pérez, I., Astorga, J. M., Rodríguez-Carrillo, A., Plaza-Díaz, J., & Fontana, L. (2018) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph15081747 · Cited by 350 · see citing works

Precision medicine in the era of artificial intelligence: implications in chronic disease management

Subramanian, M., Wojtusciszyn, A., Favre, L., Boughorbel, S., Shan, J., Letaief, K. B., Pitteloud, N., & Chouchane, L. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02658-5 · Cited by 362 · see citing works

Hypoxia‐inducible factor‐1α/interleukin‐1β signaling enhances hepatoma epithelial–mesenchymal transition through macrophages in a hypoxic‐inflammatory microenvironment

Zhang, J., Zhang, Q., Lou, Y., Fu, Q., Chen, Q., Wei, T., Yang, J., Tang, J., Wang, J., Chen, Y., et al. (2018) · Hepatology · doi:10.1002/hep.29681 · Cited by 286 · see citing works

From inflammation to cancer

Korniluk, A., Koper, O., Kemona, H., & Dymicka-Piekarska, V. (2017) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-016-1464-0 · Cited by 282 · see citing works

Association between Systemic Immunity-Inflammation Index and Hyperlipidemia: A Population-Based Study from the NHANES (2015–2020)

Mahemuti, N., Jing, X., Zhang, N., Liu, C., Li, C., Cui, Z., Liu, Y., & Chen, J. (2023) · Nutrients · doi:10.3390/nu15051177 · Cited by 260 · see citing works

Development of PARP and immune-checkpoint inhibitor combinations

Stewart, R. A., Pilié, P. G., & Yap, T. A. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-2652 · Cited by 239 · see citing works

The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment

Hendry, S. A., Farnsworth, R. H., Solomon, B., Achen, M. G., Stacker, S. A., & Fox, S. B. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00621 · Cited by 188 · see citing works

MLL1 is essential for the senescence-associated secretory phenotype

Capell, B. C., Drake, A. M., Zhu, J., Shah, P. P., Dou, Z., Dorsey, J., Simola, D. F., Donahue, G., Sammons, M., Rai, T. S., et al. (2016) · Genes & Development · doi:10.1101/gad.271882.115 · Cited by 156 · see citing works

Inflammatory factor TNF-α promotes the growth of breast cancer via the positive feedback loop of TNFR1/NF-κB (and/or p38)/p-STAT3/HBXIP/TNFR1

Cai, X., Cao, C., Li, J., Chen, F., Zhang, S., Liu, B., Zhang, W., Zhang, X., & Ye, L. (2017) · Oncotarget · doi:10.18632/oncotarget.16873 · Cited by 111 · see citing works

Immune-inflammatory responses in the elderly: an update

Accardi, G., & Caruso, C. (2018) · Immunity & Ageing · doi:10.1186/s12979-018-0117-8 · Cited by 102 · see citing works

Body fatness associations with cancer: evidence from recent epidemiological studies and future directions

Larsson, S. C., Spyrou, N., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155326 · Cited by 89 · see citing works

The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy

Shi, C., Qin, K., Lin, A., Jiang, A., Cheng, Q., Liu, Z., Zhang, J., & Luo, P. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02469-0 · Cited by 85 · see citing works

The Role of Solute Carrier Transporters in Efficient Anticancer Drug Delivery and Therapy

Puris, E., Fricker, G., & Gynther, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020364 · Cited by 58 · see citing works

Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations

Ascierto, P. A., Capone, M., Grimaldi, A. M., Mallardo, D., Simeone, E., Madonna, G., Roder, H., Meyer, K., Asmellash, S., Oliveira, C., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0569-1 · Cited by 30 · see citing works

Protein kinase inhibitors as therapeutics in neurodegenerative and psychiatric disorders

Tridente, G., Jana, A., Nath, A., & Ashraf, G. M. (2023) · Receptor Tyrosine Kinases in Neurodegenerative and Psychiatric Disorders · doi:10.1016/b978-0-443-18677-6.00015-4 · Cited by 8 · see citing works

The Innate Immune System

Heeg, K. M. (2007) · Neuroimmune biology · doi:10.1016/s1567-7443(07)00205-0

Aspects of the innate and adaptive immune responses to acute infections with BVDV

Brackenbury, L. S., Carr, B. V., & Charleston, B. (2003) · Veterinary Microbiology · doi:10.1016/j.vetmic.2003.09.004 · Cited by 58 · see citing works

Do adaptive immune cells suppress or activate innate immunity?

Zhao, J., Yang, X., Auh, S. L., Kim, K. D., Tang, H., & Fu, Y. (2008) · Trends in Immunology · doi:10.1016/j.it.2008.10.003 · Cited by 40 · see citing works

Earthworm and innate immunity

Liu, Z., & Niu, B. (2008) · Int J Immunol · doi:10.3760/cma.j.issn.1673-4394.2008.04.005

Innate and adaptive immunity

Noakes, P. S., & Michaelis, L. J. (2013) · Elsevier eBooks · doi:10.1533/9780857095749.1.3 · Cited by 12 · see citing works